Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.6800 (-8.68%) ($3.6800 - $3.6800) on Mon. Apr. 18, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.61% (three month average) | RSI | 37 | Latest Price | $3.6800(-8.68%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -3.6% a day on average for past five trading days. | Weekly Trend | AUTL declines -2.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) PAVE(84%) XBI(82%) IBB(78%) XLK(71%) INDA(69%) | Factors Impacting AUTL price | AUTL will decline at least -1.805% in a week (0% probabilities). TIP(-89%) UNG(-67%) SHY(-36%) XLU(-33%) USO(-16%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.805% (StdDev 3.61%) | Hourly BBV | -1.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-5.45(-248.1%) | Resistance Level | $4.27 | 5 Day Moving Average | $4.03(-8.68%) | 10 Day Moving Average | $4.26(-13.62%) | 20 Day Moving Average | $4.27(-13.82%) | To recent high | -21.4% | To recent low | 5% | Market Cap | $192m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |